There is less of a tendency to perform SCLD in the luminal A group. On stratified analyses, patients with non-luminal A tumors with 4-9 positive axillary lymph nodes who underwent SCLD with RT had both superior OS (HR =5.296 95% CI: 1.857–15.107 P=0.001) and DFS (HR =5.331 95% CI: 2.348–12.108 P<0.001) compared with those who received RT alone.Ĭonclusions: SCLD may not beneficial in improving survival for unselected breast cancer patients with ISLNM. However, SCLD with RT was not associated with superior survival on both univariate and multivariate analyses. The 3- and 5-year overall survival (OS) and disease-free survival (DFS) rates were 79.5% and 73.9%, respectively, and 67.5% and 54.8%, respectively. Synchronous ISLM without distant metastases were present in 3.6% cases. Among the patients included, 146 and 159 received SCLD with radiotherapy (RT) and RT alone, respectively. Results: Overall, 9,236 women presented with breast cancer during the study period. 305 patients who were recently diagnosed with ISLM were eligible for the analysis. The median duration of follow-up was 36 months (2–175 months). Methods: Data on patients presenting with breast cancer to the Breast Disease Center, Southwest Hospital, The Army Medical University from January 2004 and December 2017 were retrospectively screened. We evaluated the role of SCLD in the treatment of breast cancer with ISLM and identified patients who may benefit from SCLD. Xiang Ai 1, Minghao Wang 1, Junyan Li 2, Ying Hu 1, Lingmi Hou 3, Xiaodong Zheng 4, Yuzhao Yan 1, Qinwen Pan 1, Yuting Jin 1, Wei Liu 1, Xuanni Tan 1, Yuan Tian 1, Yi Zhang 1, Peng Tang 1, Jun Jiang 1ġBreast Disease Center, Southwest Hospital, The Army Military Medical University, Chongqing 400038, China 2Department of Breast Surgery, People’s Hospital of DeYang City, Deyang 618000, China 3Department of Thyroid Breast Surgery, First Affiliated Hospital, North Sichuan Medical College, Nanchong 637000, China 4Department of Breast Surgery, Chongqing University Cancer Hospital, Chongqing 40044, ChinaĬontributions: (I) Conception and design: P Tang, J Jiang (II) Administrative support: P Tang, J Jiang (III) Provision of study materials or patients: X Ai (IV) Collection and assembly of data: X Zheng, Y Yan, Q Pan, Y Jin, W Liu, X Tan, Y Tian (V) Data analysis and interpretation: J Li, Y Hu, L Hou, Q Pan, X Tan (VI) Manuscript writing: All authors (VII) Final approval of manuscript: All authors.īackground: The role of supraclavicular lymph node dissection (SCLD) in the treatment of breast cancer with ipsilateral supraclavicular lymph node metastasis (ISLM) remains controversial. Policy of Dealing with Allegations of Research Misconduct.Policy of Screening for Plagiarism Process.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |